Subscribe to our Newsletters !!


    Harbour BioMed and Viva Biotech declare key coordinated effort to promote biotech new startups

    HBM will combine its top Harbour Mice® stage H2L2 and its expertise in global research and development of innovative molecules, with Viva Biotech’s structure-based early phase drug discovery services. This complementary partnership will provide advanced biotech startups access to next generation technologies that create synergies to accelerate the route between ideation to merchandise. The incubated

    Polygenic threat ratings from multi-populace information should enhance IBD predictions

    Using genetic data from nearly 30,000 individuals, Mount Sinai researchers have assembled hazard scores from a combination of datasets representing distinct ancestral populations that improve prediction of risk for inflammatory bowel diseases (IBD) including Crohn’s disease and ulcerative colitis. The research was published in Gastroenterology on December 24. The researchers found that polygenic risk scores,